KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Goodwill (2016 - 2025)

Astrazeneca has reported Goodwill over the past 11 years, most recently at $21.2 billion for Q4 2025.

  • Quarterly results put Goodwill at $21.2 billion for Q4 2025, up 1.03% from a year ago — trailing twelve months through Dec 2025 was $21.2 billion (up 1.03% YoY), and the annual figure for FY2025 was $21.2 billion, up 1.03%.
  • Goodwill for Q4 2025 was $21.2 billion at Astrazeneca, up from $21.0 billion in the prior quarter.
  • Over the last five years, Goodwill for AZN hit a ceiling of $21.2 billion in Q4 2025 and a floor of -$314.0 million in Q4 2021.
  • Median Goodwill over the past 5 years was $19.8 billion (2022), compared with a mean of $12.3 billion.
  • Biggest five-year swings in Goodwill: crashed 102.58% in 2021 and later soared 6817.25% in 2024.
  • Astrazeneca's Goodwill stood at -$314.0 million in 2021, then soared by 6412.1% to $19.8 billion in 2022, then plummeted by 101.58% to -$313.0 million in 2023, then soared by 6817.25% to $21.0 billion in 2024, then increased by 1.03% to $21.2 billion in 2025.
  • The last three reported values for Goodwill were $21.2 billion (Q4 2025), $21.0 billion (Q4 2024), and -$313.0 million (Q4 2023) per Business Quant data.